ISB researchers and their collaborators are looking beyond the one-drug, one-solution approach that has thus far failed in Alzheimer’s disease research. Instead, they are focusing on other promising research avenues, such as the possible role of the gut microbiome in dementia.
Findings from the ISB-Swedish COVID-19 Immune Response Study suggest that treatments aimed at arresting the infection at the stage of moderate severity may be most effective. The team studied 139 patients and found that mild COVID-19 is very distinct from the moderate or severe forms of disease, which appear surprisingly similar.
Like the draft “shotgun” Human Genome Project of the Human Genome Organization (HUGO), the HPP has now reached a significant decadal milestone of more than 90 percent completion of the Human Proteome that is referred to as the human proteome “parts list.”
In findings published in the journal Nature Communications, researchers show that cancer cells can take more than one path to reach a drug-resistant cell state. These findings could have promising implications for the future of cancer care.
ISB researchers have unveiled new insights on how Mycobacterium tuberculosis, the pathogen that causes tuberculosis, enters and exits a dormant state in human hosts. About a quarter of the world’s population has latent TB, so these important findings will enable and accelerate the discovery of more effective TB drugs.
In the cellular process of differentiation, information about the concentrations of an important class of proteins residing in a cell’s nucleus has been lacking, a missing link needed for scientists to fully understand how the process works. ISB researchers have quantified this important class of proteins that play a key role in the formation of red blood cells.
ISB and Swedish Medical Center launched a study to follow hundreds of patients who contract COVID-19 to learn why those infected have drastically different outcomes. “Each of the COVID-19 patients has a unique lesson to teach us about how the medical and scientific community can respond most effectively to this pandemic,” said ISB President Dr. Jim Heath, who co-leads the study.
A promising new open-source metabolic modeling tool provides microbiome researchers a path forward in predicting ecosystem function from community structure. News of the software package, called MICOM, was developed in part by researchers in ISB’s Gibbons Lab, and its uses were published in the journal mSystems.
ISB researchers and their collaborators are using systems biology approaches to learn how the malaria parasite is able to transfer to humans via the bite of an infected mosquito. The information they have uncovered may help identify new ways to prevent people from contracting the deadly disease.
We created a new brand identity — including logo and tag line — to reflect ISB’s evolution since our inception in 2000, and ahead of our 20th anniversary. ISB is proud to be a part of the vibrant research community in Seattle, and is committed to translational and collaborative science.
Members of ISB’s Heath Lab and their collaborators have developed a way to sensitively detect and analyze neoantigen-specific T-cell populations from tumors and blood. This promising development may have implications for creating targeted, individual-specific cancer vaccines.
Predicting the alpha diversity of an individual’s gut microbiome is possible by examining metabolites in the blood. The robust relationship between host metabolome and gut microbiome diversity opens the door for a fast, cheap and reliable blood test to identify individuals with low gut diversity.
By using single-cell analysis to measure metabolic activities in rare disseminated tumor cells taken from non-small cell lung cancer (NSCLC) patients, ISB researchers and their collaborators can accurately predict how patients will respond to various cancer therapies, and how treatments will impact a patient’s physiological performance and survival.
ISB has entered into a scientific partnership with the Brain Health & Research Institute (BHRI), which opens its doors on September 3 in Seattle. BHRI was created by brain health expert Dr. Mary Kay Ross, and is dedicated to the evaluation, prevention, and treatment of neurodegenerative diseases, including Alzheimer’s Disease and dementia.
Brain health expert Dr. Mary Kay Ross announced the creation of the Brain Health & Research Institute (BHRI) in Seattle, and a scientific collaboration with ISB. Through that partnership, BHRI will blend the practical application of medical therapies and treatment protocols with ten advanced scientific analysis now available through personalized medicine and computational biology.
FOR IMMEDIATE RELEASE ISB Receives $3.4 Million Extension to NIH Contract to Continue Development of ‘Cancer Genomics Cloud’ with Google and CSRA SEATTLE, Oct. 21, 2016 – Institute for Systems Biology (ISB) has received a $3.4 million, one-year extension to an existing federally-funded contract from the National Cancer Institute (NCI), National Institutes of Health (NIH). This follows the completion of the initial two-year, $6.5 million contract during which ISB developed…
This week, Vice President Biden delivered an extensive update on the progress of the Cancer Moonshot initiative. ISB was mentioned in relation to the Cancer Genomics Cloud project. Learn more about ISB CGC at isb-cgc.org. Excerpt from the official White House press release: Official White House press release Full Cancer Moonshot Report Puget Sound Business Journal article
ISB researchers and their colleagues from the Center for Infectious Disease Research held the 5th annual joint poster session on June 30. The event kicked off with lightning talks, which featured two-minute research summaries from each scientist who submitted a poster. Following the lightning talks, researchers were able to peruse posters and chat with colleagues about any potential collaborations. ISB and CIDResearch takes turns hosting the event, which is intended…
